- Home
- AVDX vs SRPT Comparison
AVDX vs SRPT Comparison
Compare AVDX & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDX
- SRPT
- Stock Information
- Founded
- AVDX 2000
- SRPT 1980
- Country
- AVDX United States
- SRPT United States
- Employees
- AVDX N/A
- SRPT N/A
- Industry
- AVDX EDP Services
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- AVDX Technology
- SRPT Health Care
- Exchange
- AVDX Nasdaq
- SRPT Nasdaq
- Market Cap
- AVDX 2.0B
- SRPT 1.7B
- IPO Year
- AVDX 2021
- SRPT 1997
- Fundamental
- Price
- AVDX $9.85
- SRPT $13.32
- Analyst Decision
- AVDX Hold
- SRPT Hold
- Analyst Count
- AVDX 15
- SRPT 27
- Target Price
- AVDX $10.04
- SRPT $50.46
- AVG Volume (30 Days)
- AVDX 1.9M
- SRPT 11.5M
- Earning Date
- AVDX 07-30-2025
- SRPT 08-06-2025
- Dividend Yield
- AVDX N/A
- SRPT N/A
- EPS Growth
- AVDX N/A
- SRPT N/A
- EPS
- AVDX 0.01
- SRPT N/A
- Revenue
- AVDX $441,284,000.00
- SRPT $2,233,371,000.00
- Revenue This Year
- AVDX $5.63
- SRPT $19.93
- Revenue Next Year
- AVDX $9.83
- SRPT N/A
- P/E Ratio
- AVDX $1,102.23
- SRPT N/A
- Revenue Growth
- AVDX 10.46
- SRPT 59.15
- 52 Week Low
- AVDX $6.61
- SRPT $12.24
- 52 Week High
- AVDX $12.93
- SRPT $150.48
- Technical
- Relative Strength Index (RSI)
- AVDX 68.08
- SRPT 30.32
- Support Level
- AVDX $9.83
- SRPT $12.24
- Resistance Level
- AVDX $9.88
- SRPT $14.54
- Average True Range (ATR)
- AVDX 0.02
- SRPT 1.68
- MACD
- AVDX -0.01
- SRPT 0.27
- Stochastic Oscillator
- AVDX 54.55
- SRPT 10.17
About AVDX AvidXchange Holdings Inc.
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.